Skip to main content
QSI logo

QSI · Quantum-Si Inc

Track QSI — free
$0.91 -0.16 (-15.05%) At close · Nov 20
Market Cap
$199.75M
Shares
219.74M
Volume · Nov 20 7.82M Avg daily vol (3M) 6.87M

Price & Indicators

 

Key stats

Close
$0.91
Fri 20 Nov
Open
$1.02
Fri 20 Nov
Average volume, 30 days
7.4M
shares a session
Short interest
12.7M
5.8% of shares · 1.5 days to cover
Day range
$0.89$1.04
Open $1.02 Close $0.91
52-week closing range
$0.70$1.75
Close $0.91 48.1% under the high
Short volume, last session
45%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Nov 2020 to Nov 2026

Up next

Mar 2, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 18
Current report 8-K
Proteus Detects All 20 Amino Acids, Ahead of Year-End Goal

Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.

Regulation FD disclosure
2 source passages
it has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule Quantum-Si is now working to incorporate 20 amino acid detection into a developmental sequencing kit for use on Proteus instruments Open the document at this passage
Nov 5
Earnings call
Proteus launch remains on track for second quarter 2027

Quantum SI says Proteus remains on track for a second quarter 2027 launch, expects detection of the 20th amino acid before the end of the year, and has sufficient capital through the fourth quarter of 2028.

4 source passages
Proteus remains on track for launch in the second quarter of 2027. Based on the progress we have made and the pace of advancement we are seeing, we believe we are well positioned to demonstrate detection of the 20th amino acid before the end of the year. We continue to believe we have sufficient capital to execute the key activities required for the Proteus launch and fund operations into the fourth quarter of 2028. We firmly believe that current revenue does not capture Quantum SI's long-term value potential. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 59.0%; restructuring cuts 20% of workforce

Quantum-Si reported nine-month revenue down 59.0% and net loss of $67.5 million, while an August 2026 restructuring terminated approximately 20% of its 152 employees. Proteus is estimated to launch in the second quarter of 2027.

Revenue $212K ▼ 61.6% Net loss $22.32M Diluted EPS -$0.10
Read from the MD&A section
4 source passages
Total revenue for the sale of our Platinum line of instruments, related reagent kits and service maintenance contracts decreased by $0.3 million, or 61.6%, and $1.2 million, or 59.0%, for the three and nine months ended September 30, 2026, respectively, when compared to the same periods in 2025. Net cash used in operating activities was $64.6 million during the nine months ended September 30, 2026. Net cash used was primarily attributable to our net loss of $67.5 million, resulting from continued spend on research and development and commercialization efforts. As a result, we terminated approximately 20% of our 152 employee workforce. ProteusTM, our next-generation platform, which was announced in November 2024 and is estimated to be launched in the second quarter of 2027. Open the document at this passage
Nov 5
Current report 8-K
Proteus on track for Q2 2027 launch despite lower revenue

Quantum-Si reported third-quarter revenue of $212,000, down from $552,000, as the Platinum-to-Proteus transition continued. Proteus remains on track for a Q2 2027 launch, while 2026 revenue guidance stayed at approximately $1.0 million and cash runway was reaffirmed into Q4 2028.

Financial results
5 source passages
Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update Proteus™ remains on track for anticipated Q2 2027 commercial launch For the third quarter of 2026, the Company recorded revenue of $212,000, compared to $552,000 in the third quarter of 2025. Revenue: Approximately $1.0 million The Company believes its cash, cash equivalents and investments in marketable securities of $149.4 million as of September 30, 2026, together with its cost-reduction actions, will support the Company’s operating plan into the fourth quarter of 2028. Open the document at this passage
Oct 15
Current report 8-K Events of Oct 14
Regains Nasdaq Minimum Bid Price Compliance as of October 13

Quantum-Si regained compliance with Nasdaq's minimum bid price requirement as of October 13, 2026, closing the matter. The company will keep monitoring its bid price, and a future shortfall could again trigger delisting notice.

Other events
3 source passages
On October 14, 2026, the Staff notified the Company that, as of October 13, 2026, the Company had regained compliance with the Bid Price Requirement and that the matter is now closed. The Company will continue to monitor the closing bid price of its Common Stock in the future. If the Company does not maintain compliance with Nasdaq Listing Rule 5450(a)(1) in the future, it is likely that Nasdaq will once again provide notice that the Company’s Class A common stock will be subject to delisting. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$1.26M
Trailing 12 months
Net income (TTM)
−$85.13M
Trailing 12 months
Revenue growth YoY
-61.6%
Year over year
Operating margin
-7,474.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$25.58M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
-26.7%
Trailing year
Short interest
5.8%
Latest settlement · 1.5 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Quantum-Si pushed the Proteus launch from end of 2026 to Q2 2027 to add an extra integrated instrument design cycle, announced a ~20% workforce reduction expected to deliver ~$12M in annualized savings, and extended its cash runway into Q4 2028 while reiterating 2026 guidance.

Bullish
  • + Cash runway extended into Q4 2028 from Q2 2028 following cost actions
  • + Management identifies a >$4B non-human proteomics market opportunity for Proteus
  • + Strategic shift to application-oriented library prep kits expected to expand capabilities and reduce technical risk
  • + Net loss narrowed to $23.5M in Q2 2026 from $28.8M in Q2 2025
Bearish
  • − Proteus launch pushed from end of 2026 to Q2 2027 to add an extra instrument design cycle
  • − Q2 2026 revenue fell 42% YoY to $344K as Platinum-to-Proteus transition dampens demand
  • − Q2 2026 gross margin of 50% impacted by mix and transition-period commercial activity; H1 2026 gross margin was 41%

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −22%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 20%
mid-range
Momentum
relative strength
Very Weak
1-month return −35%
trailing
6-month return −27%
trailing
YTD return −17%
this year
Relative strength −18%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-18% holders QoQ · +14 funds added
Insider flow Distributing
Net -$39.4K over 90 days · 100% sells
Short interest Falling
5.78% of shares out · ▼ -3.8% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — mid 3-yr range
Squeeze score 48
elevated · 0–100
Fundamentals
Fair
Revenue growth −20%
Y/Y
Gross margin 47%
contracting
EPS growth +28%
Y/Y
Free cash flow $-97.2M
Quant / Vol
risk profile
Very High
Volatility 103%
annualized · 1-yr
Max drawdown −52%
past year
ATR 17.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
full year 2026
Revenue Maintained $1M
Aug 13, 2026 $1M changed to Nov 5, 2026 $1M
prior FY $2.44M midpoint −58.9% Y/Y
Adjusted operating expenses Non-GAAP up to $87M
Total cash usage up to $87M
annualized
Annualized operating expense savings $12M
Previous outlook earlier release · from the Earnings Call filed Aug 13, 2026

Still-open targets the latest release did not restate under the same label.

Annual operating expense savings · annual $12M
Adjusted operating expenses · full year 2026 up to $98M
Total cash usage · full year 2026 up to $93M
Guided vs delivered · last 1 settled
Revenue full year 2024
guided $3.7M – $4.2M
$3.06M Miss −22.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−22% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
-18% holders QoQ · +14 funds added
Insider flow Distributing
Net -$39.4K over 90 days · 100% sells
Short interest Falling
5.78% of shares out · ▼ -3.8% MoM · 1.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
116 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 20% Range high $2
vs 200-day avg -6% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Cash, cash equivalents and investments in marketable securities $149.4M As of September 30, 2026 —
Reduction in force 20% second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
QSI
Quantum-Si Inc
this stock
$199.75M -17.4% -20.3% — 5.8%
ABT
Abbott Laboratories
$178.39B -17.8% +5.7% 38.4 1.1%
MDT
Medtronic plc
$127.84B +4.0% +8.4% 24.6 1.8%
SYK
Stryker Corp
$118.01B -11.8% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$60.85B -56.0% +12.5% 17.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
116
% held
19.6%
Net QoQ
-9.9M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
31
View
Short & Settlement
Short Interest Falling
Shares short
12.7M
Days to cover
1.5d
Change
-505.1K sh
View
Short Volume
Short vol %
45%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
4.3K
Value
$5.0K
As of
Oct 21, 2026
View
Off-Exchange
Off-exchange %
61.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$39.4K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$2.4M
Net income (FY)
$-101.3M
EPS diluted
$-0.51
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 18, 2026
This year
20

Quantum-Si has demonstrated detection of all 20 naturally occurring amino acids in its Proteus development program, achieving its year-end 2026 goal ahead of schedule. It is working to incorporate that detection into a developmental sequencing kit for Proteus instruments.

View
Proposed Sales
Value
$11.0K
Shares
14.5K
Filed
Sep 23, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Quantum-Si Announces Inducement G…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
QSI -21.0% -35.1% -26.7% -37.7% -17.4%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -12.4% -25.8% -17.5% -29.0% -18.5%
Key facts CIK 1816431 CUSIP 74765K105 13F (30d) 123 filings 103 filers Visit website Investor relations